Mohammed Milhem
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mohammed Milhem sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Mohammed Milhem: 7 sponsored US clinical trials, 1 recruiting.
Mohammed Milhem sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC), with 1 trials.
Upper-quartile sponsor footprint
Mohammed Milhem sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
NCT07404332
Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
NCT05363631
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
NCT03173976
Chlorpromazine and Standard of Care in Glioblastoma
NCT05190315
High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas
NCT03508726
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
NCT02959164
SLM + Axitinib for Clear Cell RCC
NCT02535533
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
What is open in the Mohammed Milhem pipeline
1 recruiting of 7 indexed (14% open); 4 completed (57%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mohammed Milhem: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Mohammed Milhem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Mohammed Milhem page
7 registered trials is a research-attention snapshot, not an endorsement of Mohammed Milhem or any single study.
- 1 of Mohammed Milhem's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) is the condition Mohammed Milhem studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mohammed Milhem pipeline card: 7 registered trials from official public datasets.Report a data error.